Given that DF has been conducting research on p53 for over a decade, it is hard for me to believe that they would continue to conduct the Kevetrin p1 trial if it weren't showing some sort of measurable results. Activation of p53 (w/o tumor shrinkage) alone would be momentous. With shrinkage it gets even better. Plenty of reasons to be optimistic about the K at this time.
The company has been talking more than just the safety profile thru these cohorts. Biotech shows and press releases laid out that there may be decent efficacy. Yes, we'll see, but the idea here is to show enough efficacy in phase 1 so they can achieve FDA breakthrough designation and what tumors react best. So we march on.
News 
Market Data 
Discover 
AI
